39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2019 at "CNS Spectrums"
DOI: 10.1017/s1092852919000324
Abstract: Abstract Objective To evaluate the long-term safety and tolerability of once-dailyvalbenazine in adults with tardive dyskinesia(TD). Methods Data were pooled from KINECT 3 (NCT02274558: 6-week double-blind placebo-controlled period, followed by a 42-week double-blind extension and… read more here.
Keywords: valbenazine; study; long term; week ... See more keywords
Long-Term Effects of Once-Daily Valbenazine in Older and Younger Adults with Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000335
Abstract: Abstract Introduction Older patients taking a dopamine receptor blocking agent (eg, first- or second-generation antipsychotic) have an increased risk for tardive dyskinesia (TD), a persistent and potentially disabling movement disorder. Valbenazine, a selective and potent… read more here.
Keywords: valbenazine; long term; tardive dyskinesia; cgi pgic ... See more keywords
A Model-Informed Drug Development Approach Supporting the Approval of a New Valbenazine Dose for Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000402
Abstract: Abstract Introduction Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with dopamine receptor blocking agents (eg, antipsychotics). Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor with several safe and… read more here.
Keywords: tardive dyskinesia; development; model; aims cfb ... See more keywords
Sustained Treatment Response With Long-Term Valbenazine in Patients With Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2023 at "CNS Spectrums"
DOI: 10.1017/s1092852923001712
Abstract: Abstract Background Valbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics, antiemetics, and other dopamine receptor blocking… read more here.
Keywords: tardive dyskinesia; valbenazine; score; week ... See more keywords
Drug-Drug Interactions with Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice
Sign Up to like & getrecommendations! Published in 2024 at "CNS Spectrums"
DOI: 10.1017/s1092852924001639
Abstract: Introduction Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved for tardive dyskinesia (TD) treatment in adults. To prevent potential drug-drug interactions (DDIs), valbenazine labeling recommends doses 40 mg/day when taking strong CYP3A4 or… read more here.
Keywords: risk; deutetrabenazine; drug; proportions patients ... See more keywords
Valbenazine Improves Tardive Dyskinesia with or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials
Sign Up to like & getrecommendations! Published in 2024 at "CNS Spectrums"
DOI: 10.1017/s1092852924001883
Abstract: Introduction Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor indicated for tardive dyskinesia (TD), a persistent and potentially debilitating movement disorder associated with prolonged antipsychotic exposure. Given the paucity of data regarding the… read more here.
Keywords: meta analysis; long term; term valbenazine; analysis ... See more keywords
Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Psychopharmacology"
DOI: 10.1097/jcp.0000000000001860
Abstract: Abstract Purpose/Background Using data from KINECT® 4, a phase 3, 48-week study of valbenazine, post hoc analyses were conducted to assess long-term outcomes that are relevant to the real-world management of tardive dyskinesia (TD). Methods/Procedures… read more here.
Keywords: week; treatment; long term; response ... See more keywords
Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70390
Abstract: Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia and Huntington's chorea. Dysphagia, pill aversion, and fear of swallowing are common in patients with these conditions. A new… read more here.
Keywords: oral administration; valbenazine sprinkle; sprinkle; sprinkle capsule ... See more keywords
Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Psychopharmacology"
DOI: 10.1177/02698811241248391
Abstract: Background: Valbenazine is used for tardive movement disorders in adults. Current studies on its safety are mostly from clinical trials and small case reports, limiting information on rare adverse reactions. This study investigated valbenazine-related adverse… read more here.
Keywords: system; administration; drug; adverse event ... See more keywords
Successful Electroconvulsive Therapy for Tardive Dyskinesia and Tardive Dystonia Refractory to Valbenazine Treatment: A Case Report and Narrative Literature Review
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Psychopharmacology and Neuroscience"
DOI: 10.9758/cpn.24.1185
Abstract: Tardive dyskinesia and dystonia are intractable extrapyramidal symptoms caused by the blockade of dopamine receptors by antipsychotic drugs. In addition to the reduction or discontinuation of the causative drug, valbenazine for tardive dyskinesia and botulinum… read more here.
Keywords: electroconvulsive therapy; tardive dystonia; valbenazine; tardive dyskinesia ... See more keywords